正業科技(300410.SZ):實控人被列入失信被執行人名單
格隆匯5月30日丨正業科技(300410.SZ)公佈,公司於2020年1月16日披露了《關於實際控制人涉及訴訟的公吿》(公吿編號:2020-005),披露了實際控制人徐地華、徐國鳳發生的相關訴訟事項。公司於近日通過中國執行信息公開網公示信息查詢,獲悉公司實際控制人徐地華、徐國鳳因上述事項被東莞市中級人民法院列入失信被執行人名單。
公司實際控制人被列入失信被執行人名單不影響公司正常生產經營、管理活動,公司將持續關注該事項的進展,嚴格按照相關法律、法規及規範性文件的要求及時履行信息披露義務,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.